Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure

Front Immunol. 2024 Apr 30:15:1377374. doi: 10.3389/fimmu.2024.1377374. eCollection 2024.

Abstract

Respiratory syncytial virus (RSV) is the primary cause of bronchiolitis-related hospitalizations among children under 5 years of age, with reinfection being common throughout life. Maternal vaccination has emerged as a promising strategy, delivering elevated antibody levels to newborns for immediate protection. However, limited research has explored the protective efficacy of maternal antibodies (matAbs) against secondary RSV infections in offspring. To address this gap, we employed a mouse model of maternal RSV vaccination and secondary infection of offspring to evaluate lung pathology following RSV reinfection in mice with varying levels of maternal antibody (matAb). Additionally, we aimed to investigate the potential causes of exacerbated lung inflammation in offspring with high matAb levels following secondary RSV exposure. Our findings revealed that offspring with elevated levels of maternal pre-F antibody demonstrated effective protection against lung pathology following the initial RSV infection. However, this protection was compromised upon reinfection, manifesting as heightened weight loss, exacerbated lung pathology, increased expression of RSV-A N genes, eosinophilia, enhanced IL-5, IL-13, MUC5AC, and eosinophils Major Basic Protein (MBP) production in lung tissue compared to offspring lacking matAbs. Importantly, these unexpected outcomes were not attributed to antibody-dependent enhancement (ADE) resulting from declining matAb levels over time. Notably, our findings showed a decline in secretory IgA (sIgA), mucosal IgA, and mucosal IgG levels in offspring with high matAb levels post-primary RSV challenge. We propose that this decline may be a critical factor contributing to the ineffective protection observed during secondary RSV exposure. Overall, these findings offer valuable insights into maternal vaccination against RSV, contributing to a comprehensive understanding and mitigation of potential risks associated with maternal RSV vaccination.

Keywords: maternal immunization; mucosal immunity; respiratory syncytial virus; secondary RSV exposure; type 2 inflammation.

MeSH terms

  • Animals
  • Antibodies, Viral* / blood
  • Antibodies, Viral* / immunology
  • Disease Models, Animal
  • Female
  • Immunity, Maternally-Acquired
  • Lung / immunology
  • Lung / pathology
  • Lung / virology
  • Mice
  • Mice, Inbred BALB C
  • Pneumonia* / immunology
  • Pregnancy
  • Respiratory Syncytial Virus Infections* / immunology
  • Respiratory Syncytial Virus Vaccines / administration & dosage
  • Respiratory Syncytial Virus Vaccines / adverse effects
  • Respiratory Syncytial Virus Vaccines / immunology
  • Respiratory Syncytial Viruses / immunology

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (Grant: 8187011078, 8217060624), Program for Youth Innovation in Future Medicine, Chongqing Medical University (Number: W0063), General Program of Natural Science Foundation of Chongqing (Number: CSTB2022NSCQ-MSX0822), and Zhuhai Innovative and Entrepreneurial Research Team Program (Number: 2120004000202).